3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
4
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Non-Metastatic
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Breast Neoplasms
1
Biochemically Recurrent Prostate Cancer
1
Interventions
enzalutamide
6
Abiraterone Acetate
4
niraparib
2
Prednisone
2
xentuzumab
1
tasquinimod
1
pembrolizumab
1
darolutamide
1
atezolizumab
1
abiraterone
1
Nivolumab
1
Drug Therapy
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
Clear all
NCT04157088
2023-08-04
DaroAcT
Bayer
Phase 2
Terminated
30 enrolled
25 charts